AstraZeneca: Atypical Hemolytic Uremic Syndrome trials

The registry lists 19 Atypical Hemolytic Uremic Syndrome studies with AstraZeneca as lead sponsor. 4 are open to participants now and 9 have results posted.

Phase 2 7Phase 3 2Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ravulizumab Outcomes in Polish Patients With aHUSRecruitingNCT07399730
• Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUSRecruitingNCT07308574Phase 4
• Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecruitingNCT06312644
• Atypical Hemolytic-Uremic Syndrome (aHUS) RegistryRecruitingNCT01522183
• Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT03131219Phase 3Results posted
• Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT02949128Phase 3Results posted
• Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and TreatmentTerminatedNCT02614898Results posted
• An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic SyndromeCompletedNCT01194973Phase 2Results posted
• An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic SyndromeCompletedNCT01193348Phase 2Results posted
• Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUSCompletedNCT00844844Phase 2Results posted
• Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUSCompletedNCT00844545Phase 2Results posted
• Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUSCompletedNCT00844428Phase 2Results posted
• Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT00838513Phase 2Results posted
• The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in EgyptCompletedNCT07218536
• A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome PatientsActive, not recruitingNCT06099236
• A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT01770951
• The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT01757431Phase 2
• To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS PatientsCompletedNCT01755429
• aHUS Observational Long Term Follow-UpTerminatedNCT01522170